strains, except those with OXA-48 alone, are broadly resistant to -lactams and have multiple aminoglycoside-modifying enzymes; those with NDM-1 carbapenemase typically also have 16S rRNA methylases, conferring complete aminoglycoside resistance. In this study, the activity of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline was evaluated against 81 carbapenem-resistant Enterobacteriaceae isolates from the UK. Testing was performed by the Clinical and Laboratory Standards Institute (CLSI) agar dilution method. Chloramphenicol, ciprofloxacin and nitrofurantoin inhibited <25% of the isolates at the breakpoint, whereas colistin was active against 75/81 isolates (92.6%), the exceptions being four Klebsiella pneumoniae and Enterobacter cloacae isolates along with members of inherently resistant genera. Fosfomycin was active against 49/81 isolates (60.5%), including 7/7 Escherichia coli, 16 M a n u s c r i p t
Introduction
Carbapenem-resistant Enterobacteriaceae are increasingly prevalent in many parts of the world. They are diverse, variously producing metallo-carbapenemases (mostly NDM [1] or VIM [2] enzymes) or non-metallo-types (principally KPC [3] or OXA-48 [4] ). Most carbapenemase-producers are almost completely resistant to -lactam antibiotics except that: (i) those with OXA-48 alone remain susceptible to several oxyimino-cephalosporins [5] ; and (ii) those with metallo-carbapenemases alone, lacking AmpC or extended-spectrum -lactamases (ESBLs), remain susceptible to aztreonam [6] . Aminoglycoside resistance is extensive but more variable: strains with NDM-1 enzyme mostly co-produce an ArmA or RmtC 16S rRNA methylase, conferring broad resistance, whereas those with other carbapenemases have variable arrays of modifying enzymes, with isepamicin often spared and with gentamicin retaining activity against the internationally widespread KPC + sequence type (ST) 258 Klebsiella pneumoniae strain [7] .
Here we present susceptibility data for chloramphenicol, ciprofloxacin, colistin, fosfomycin, nitrofurantoin, minocycline and tigecycline against carbapenemaseproducers collected in the UK, selected as non--lactam and non-aminoglycoside drugs. The -lactam temocillin was also included as it has been suggested by others to have specific activity against strains with KPC carbapenemases [8] .
M a n u s c r i p t
Materials and methods

Bacteria
The strain set has been described previously [6] . It represents a diversity of carbapenem resistance types and host species, including organisms with carbapenemases and with combinations of ESBL or AmpC and impermeability, but does not comprise consecutive producer isolates, nor was it matched to the (everchanging) relative prevalence of different resistance types. Transformants and transconjugants of Escherichia coli DH5 and J62-1 with carbapenemase-encoding plasmids were prepared as described previously [7] .
Antibiotics
Chloramphenicol, ciprofloxacin, colistin, disodium fosfomycin, minocycline and nitrofurantoin were all from Sigma (Poole, UK), temocillin was from Eumedica (Brussels, Belgium) and tigecycline was from Pfizer (Sandwich, UK).
Susceptibility testing
Antibiotics were tested by the Clinical and Laboratory Standards (CLSI) agar dilution method [9] using Mueller-Hinton agar from Oxoid/Thermo Fisher (Basingstoke, UK);
glucose-6-phosphase (25 mg/L) was added for tests with fosfomycin.
Results and discussion
Minimum inhibitory concentration (MIC) distributions are shown in relation to carbapenem resistance mechanism in Table 1 and to host species in Table 2 . Table M a n u s c r i p t 2 omits temocillin since, uniquely among the compounds tested, it is a -lactam directly affected by some of the carbapenemases; it is therefore implausible that species would be the major determinant of its activity. Table 3 ).
The present results, along with previously published data for aminoglycosides [7] , underscore the considerable resistance of many carbapenemase-producers.
A c c e p t e d M a n u s c r i p t
Although colistin, fosfomycin and tigecycline were active or intermediately active against more than one-half of the study population, all have significant limitations.
Colistin is increasingly used but has nephrotoxicity and uncertain efficacy in pulmonary infections, although it appears more consistently effective in other infection types [10, 11] . Moreover, in some cases, colistin resistance is selected during therapy, and this may apply for the resistant E. cloacae with NDM-1 enzyme in the present study, which was from a child who had already received colistin for
Acinetobacter and Pseudomonas infections [12] . Furthermore, colistin-resistant variants of the international KPC + ST258 K. pneumoniae strain are circulating in
Greece and Hungary [13, 14] , with a few cases also seen in the UK. In the case of tigecycline, there are positive case reports of its use in infections due to K.
pneumoniae with VIM and KPC carbapenemases in Greece [15] , but also of resistance emerging during therapy, albeit in an off-label setting (nosocomial pneumonia) [16] . Moreover, it is licensed for use only in intra-abdominal and complicated skin and skin-structure infections, and proved inferior to imipenem/cilastatin in ventilator-associated pneumonia, providing a caution against off-label use in this infection [17] . Tigecycline is also probably not appropriate in urinary infections owing to largely biliary excretion and low urinary levels.
Fosfomycin, by contrast, may be highly appropriate for urinary infections, where it has a good reputation for efficacy [18] . On the other hand: (i) fosfomycin is not readily available in many countries, or is available only as an oral formulation for uncomplicated urinary infections; and (ii) a question mark hangs over its use as monotherapy for severe infections at other body sites in view of the borderline susceptibility of many Klebsiella spp. and the potential for resistance to emerge by mutation, although this may be less frequent in vivo than in vitro [18] .
A c c e p t e d M a n u s c r i p t
Temocillin only showed potential when reviewed against urinary breakpoints and, on these criteria, had activity against all of the isolates with carbapenem resistance contingent on combinations of ESBL or AmpC and impermeability, as well as onehalf those with KPC enzymes. The former activity is surprising since temocillin carries a double negative charge, which would be expected to impede uptake [19] ; nevertheless, the behaviour was consistent for all porin-deficient strains. The limited effect of KPC enzymes, as confirmed with transconjugant studies (Table 3) , is in keeping with the findings of Adams-Haduch et al. [8] . Although the maximum licensed dosage of 2 g intravenous twice daily can only justify a systemic breakpoint of 8 mg/L, a 2 g thrice daily regimen is under evaluation and may justify a higher breakpoint, as may 6 g daily by continuous infusion [20] . Moreover, temocillin is a close analogue of ticarcillin, which is used at dosages of up to 18 g/day, and we would urge that safety evaluations of temocillin at such dosages as a preliminary to clinical evaluation against systemic infections due to bacteria with KPC carbapenemases.
Three final points should be made. First, these results provide only a wide-angle snapshot. Carbapenem-resistant isolates from individual cases and outbreaks may be different from those examined here. For example, most ST258 K. pneumoniae with KPC carbapenemases are susceptible to gentamicin, tigecycline and colistin but, as already noted, some variants are resistant even to colistin [13, 14] , whereas non-ST258 K. pneumoniae isolates presently circulating in north-west England, and not included in the present study, often are susceptible to multiple aminoglycosides and fluoroquinolones (Health Protection Agency, data on file). Second, the present results M a n u s c r i p t suggest formulary-based interventions, e.g. preferential use of tigecycline in mild-tomoderate intra-abdominal infections and of fosfomycin (or temocillin if KPC enzymes are the concern) for urinary infections, by which a hospital might mitigate selection pressure for carbapenemase-producers. Such strategies deserve evaluation, both for their efficacy and ecological consequences. Last, for severe infections it may be appropriate to combine the few agents that remain active to maximise the chance of efficacy and to minimise selection of further resistance.
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